In Reply We thank Messerli and colleagues and Liu for their thoughtful letters and their interest in our study assessing the association between aldosterone parameters and incident cardiovascular disease.
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Unanswered Questions in Aldosteronism and Cardiovascular Risk | 0 | 8.36 | 01-08-2026 |
| 2 | Unanswered Questions in Aldosteronism and Cardiovascular Risk | 0 | 5.33 | 01-08-2026 |
| 3 | Right Ventricular Metrics as End Points in Clinical Trials | 0 | 5.8 | 01-08-2026 |
| 4 | Спасибо! | 0 | 0 | 07-07-2026 |
| 5 | Interpreting the APERITIF Randomized Clinical Trial—Reply | 0 | 10.38 | 01-08-2026 |
| 6 | Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk | 0 | 7.22 | 01-08-2026 |
| 7 | JAMA Cardiology | 0 | 7.83 | 01-08-2026 |
| 8 | Зеленский поблагодарил Алиева | 0 | 10 | 25-08-2026 |
| 9 | Comentario en El siniestro viaje de la cabeza de Oliver Cromwell por Nathaly | 0 | 8.1 | 03-06-2021 |